
Peter K Kaiser MD
Retinal Disease
Chaney Family Endowed Chair in Ophthalmology Research Professor of Ophthalmology, Cole Eye Institute, Cleveland, OH
Join to View Full Profile
9500 Euclid AveCleveland, OH 44195
Phone+1 800-223-2273
Dr. Kaiser is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Bascom Palmer Eye InstituteFellowship, 1996 - 1997
Mass General Brigham/Massachusetts Eye and Ear/Harvard Medical SchoolResidency, Ophthalmology, 1993 - 1996
Massachusetts Eye and Ear InfirmaryClinical, Ophthalmology, 1993 - 1996
Mass General Brigham/Massachusetts General HospitalInternship, Internal Medicine, 1992 - 1993
Harvard Medical SchoolClass of 1992
Certifications & Licensure
FL State Medical License 2004 - 2028
CA State Medical License 2002 - 2027
IL State Medical License 2002 - 2026
MA State Medical License 2002 - 2026
MI State Medical License 2002 - 2026
OH State Medical License 1997 - 2026
PA State Medical License 2002 - 2026
American Board of Ophthalmology Ophthalmology- Join now to see all
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2012, 2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2012, 2014, 2016-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2012, 2014, 2016-2017
Clinical Trials
- Vascular Remodeling and the Effects of Angiogenic Inhibition in Diabetic Retinopathy Start of enrollment: 2006 Jul 01
- Open-Label, Pilot Study of TG100801 in Patients With Choroidal Neovascularization Due to AMD Start of enrollment: 2007 Jul 01
- Optical Coherence Tomography in Multiple Sclerosis Patients Start of enrollment: 2012 Aug 01
Publications & Presentations
PubMed
- TALON phase IIIb study: 64 week results of brolucizumab versus aflibercept using treat-and-extend for neovascular age-related macular degeneration.Carl Regillo, Peter K Kaiser, Peter J Kertes, Mark Gillies, Tina Maio-Twofoot
Eye. 2026-02-01 - Outcomes and Complications of Pars Plana Vitrectomy for Nonclearing Vitreous Hemorrhage Without Tractional Elements.Justin C Muste, Matthew J Schulgit, Scott Perkins, Matthew Russell, Saam Mojtahed
Ophthalmology. Retina. 2026-01-29 - Swept-Source OCT and OCT Angiography B-Scan Analysis of Inflammatory Retinal Vascular Changes: Quantitative and Qualitative Assessment.Yuka Mizuno, Sunil K Srivastava, Sandeep Singh, Jon Whitney, Kimberly Baynes
Ophthalmology. Retina. 2026-01-14
Journal Articles
- HIV-1 coat protein increases intracellular Ca2+ and injures neurons: toxicity prevented by calcium channel antagonists.Dreyer EB, Kaiser PK, Offermann JT, and Lipton SA., Science 1990
- Neuronal injury due to HIV-1 envelope protein is blocked by anti-gp120 antibodies but not by anti-CD4 antibodies.Kaiser PK, Offermann JT, and Lipton SA., Neurology 1990
- VIP-mediated increase in cAMP prevents TTX-induced retinal ganglion cell death in vitro.Kaiser PK and Lipton SA., Neuron 1990
Books/Book Chapters
Abstracts/Posters
- A study of the effects of vasoactive intestinal peptide on natural cell death of retinal ganglion cells.Kaiser PK, Summa cum laude honors thesis; Harvard College
- Vasoactive intestinal peptide via cAMP rescues mammalian retinal ganglion cells from tetrodotoxin-induced death.Kaiser PK and Lipton SA, Society for Neuroscience
- Calcium channel antagonists partially prevent neuronal cell killing by HIV-1 coat protein gp120 in vitro.Campo R, Offermann JT, Arroyo JG, Kaiser PK, Chen HS V, and Lipton SA, Society for Neuroscience
Lectures
- New treatment strategies for corneal abrasions.New England Ophthalmological Society Meeting, Boston, MA
- Digital Journal of Ophthalmology and other world wide web resources for ophthalmologists.American Academy of Ophthalmology Annual Meeting
- Submacular Surgery Trials.Cleveland Ophthalmology Society Meeting
Press Mentions
OpRegen® (RG6501) 36-Month Visual Acuity Results Featured at Clinical Trials at the Summit 2025June 23rd, 2025
RG6501 (OpRegen®) Phase 1/2a Clinical Study 36 Month Results to Be Featured at Clinical Trials at the Summit 2025May 12th, 2025
Aavantgarde Closes $141 Million Series B FinancingApril 11th, 2025
Grant Support
- Vacsular Remodeling And Effects Of Angiogenic Inhibition In Diabetic RetinopathyNational Eye Institute2006
- Vascular Remodeling And Effects Of Angiogenic InhibitionNational Eye Institute2005
Professional Memberships
- Fellow
- Member
- Macula SocietyMember
- Retina SocietyMember
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:











